Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Carcinoma, Non-Small-Cell Lung drug therapy"" wg kryterium: Temat


Tytuł :
Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer
Autorzy :
Philippe Coucke
Selma Ben Mustapha
C. Mievis
François Cousin
Colin Desir
Roland Hustinx
Pokaż więcej
Temat :
Radiology Nuclear Medicine and imaging
Oncology
Hematology
Risk factor
Pneumonitis
medicine.disease
medicine
Lung cancer
Radiation therapy
medicine.medical_treatment
Population
education.field_of_study
education
Radiation recall
Immune checkpoint inhibitors
Medical record
medicine.medical_specialty
business.industry
business
Internal medicine
Aged
Carcinoma, Non-Small-Cell Lung/drug therapy
Humans
Immune Checkpoint Inhibitors
Incidence
Lung Neoplasms/drug therapy
Male
Pneumonia
Radiation Pneumonitis/epidemiology/etiology
Retrospective Studies
Risk Factors
Tomography, X-Ray Computed
Anti PD-1/PD-L1
Radiation pneumonitis
Radiation recall pneumonitis
Radiology, nuclear medicine & imaging [Human health sciences]
Radiologie, imagerie médicale et médecine nucléaire [Sciences de la santé humaine]
Źródło :
Crossref
Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 157, 47-55., Ireland. (2021).
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174028b9f6829e48a1f163a706738e89
https://api.elsevier.com/content/article/PII:S0167814021000013?httpAccept=text/xml
Tytuł :
A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer
Autorzy :
Wang, Xiangxue
Bera, Kaustav
Barrera, Cristian
Zhou, Yu
Lu, Cheng
Vaidya, Pranjal
Fu, Pingfu
Yang, Michael
Schmid, Ralph Alexander
Berezowska, Sabina
Choi, Humberto
Velcheti, Vamsidhar
Madabhushi, Anant
Pokaż więcej
Temat :
Early-stage non-small cell lung cancer
Computational pathology
Prognostic and predictive
Medicine
Medicine (General)
R5-920
General Biochemistry, Genetics and Molecular Biology
General Medicine
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/pathology
Chemotherapy, Adjuvant
Cytodiagnosis/methods
Diagnosis, Computer-Assisted/methods
Diagnosis, Computer-Assisted/standards
Female
Humans
Lung Neoplasms/drug therapy
Lung Neoplasms/pathology
Male
Middle Aged
Neoplasm Staging
Survival Analysis
610 Medicine & health
610 Medizin und Gesundheit
Research Paper
Źródło :
EBioMedicine, Vol 69, Iss, Pp 103481-(2021)
Crossref
EBioMedicine, vol. 69, pp. 103481
Wang, Xiangxue; Bera, Kaustav; Barrera, Cristian; Zhou, Yu; Lu, Cheng; Vaidya, Pranjal; Fu, Pingfu; Yang, Michael; Schmid, Ralph Alexander; Berezowska, Sabina; Choi, Humberto; Velcheti, Vamsidhar; Madabhushi, Anant (2021). A prognostic and predictive computational pathology image signature for added benefit of adjuvant chemotherapy in early stage non-small-cell lung cancer. EBioMedicine, 69(103481), p. 103481. Elsevier 10.1016/j.ebiom.2021.103481 <http://dx.doi.org/10.1016/j.ebiom.2021.103481>
EBioMedicine
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::262eeb26eada4eba93adb7f39457905d
http://www.sciencedirect.com/science/article/pii/S2352396421002747
Tytuł :
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
Autorzy :
Curioni-Fontecedro, Alessandra
Perentes, Jean Yannis
Gelpke, Hans
Xyrafas, Alexandros
Bouchaab, Hasna
Mach, Nicolas
Matzinger, Oscar
Stojcheva, Nina
Frueh, Martin
Weder, Walter
Cathomas, Richard
Gargiulo, Piera
Bubendorf, Lukas
Pless, Miklos
Betticher, Daniel
Peters, Solange
Swiss Group of Clinical Cancer Research (SAKK)
Pokaż więcej
Temat :
Adult
Aged
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/pathology
Carcinoma, Non-Small-Cell Lung/radiotherapy
Carcinoma, Non-Small-Cell Lung/surgery
Cetuximab/administration & dosage
Cetuximab/adverse effects
Chemoradiotherapy
Cisplatin/administration & dosage
Cisplatin/adverse effects
Docetaxel/administration & dosage
Docetaxel/adverse effects
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy/adverse effects
Neoplasm Staging
Progression-Free Survival
Clinic for Oncology and Hematology
Clinic for Thoracic Surgery
610 Medicine & health
ddc:616
Article
Surgical oncology
Non-small-cell lung cancer
Cancer Research
Oncology
Internal medicine
medicine.medical_specialty
medicine
Docetaxel
medicine.drug
Concomitant
Lung cancer
medicine.disease
Chemotherapy
medicine.medical_treatment
Cetuximab
Cisplatin
business.industry
business
Radiation therapy
Clinical endpoint
neoplasms
Źródło :
British journal of cancer, vol. 120, no. 10, pp. 968-974
Curioni-Fontecedro, Alessandra; Perentes, Jean Yannis; Gelpke, Hans; Xyrafas, Alexandros; Bouchaab, Hasna; Mach, Nicolas; Matzinger, Oscar; Stojcheva, Nina; Frueh, Martin; Weder, Walter; Cathomas, Richard; Gargiulo, Piera; Bubendorf, Lukas; Pless, Miklos; Betticher, Daniel; Peters, Solange (2019). Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08). British Journal of Cancer, 120(10):968-974.
British Journal of Cancer, Vol. 120, No 10 (2019) pp. 968-974
British Journal of Cancer
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505dd02a974a25c299fb36ed60ff60ed
https://serval.unil.ch/resource/serval:BIB_6DA91E6BDAAE.P001/REF.pdf
Tytuł :
Frequency of low-grade adverse events and quality of life during chemotherapy determine patients' judgement about treatment in advanced-stage thoracic cancer
Autorzy :
de Mol, Mark
Visser, Sabine
den Oudsten, Brenda L.
Lodder, Paul
van Walree, Nico
Belderbos, Huub
Aerts, Joachim G.
Pokaż więcej
Temat :
Adult
Aged
Antineoplastic Agents/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy
Drug-Related Side Effects and Adverse Reactions/psychology
Emotions
Female
Health Status
Humans
Lung Neoplasms/drug therapy
Male
Middle Aged
Patient Satisfaction/statistics & numerical data
Personal Satisfaction
Quality of Life/psychology
Surveys and Questionnaires
PHYSICIAN
Psycho-oncology
THERAPY
Adverse events
DECISION-MAKING
SYMPTOMS
SATISFACTION QUESTIONNAIRE
WORLD-HEALTH-ORGANIZATION
Anti-neoplastic therapy
PREFERENCES
Non-small cell lung cancer
EXPERIENCE
QLQ-C30
ASSESSMENT WHOQOL
Cancer Therapy Satisfaction Questionnaire
Carcinoma
Non-Small-Cell Lung/drug therapy
Original Article
Oncology
Chemotherapy
medicine.medical_treatment
medicine
Internal medicine
medicine.medical_specialty
Feeling
media_common.quotation_subject
media_common
Lung cancer
medicine.disease
Adverse effect
Cancer
Quality of life
Pain medicine
Nursing research
business.industry
business
humanities
Źródło :
Supportive Care in Cancer, 27(9), 3563-3572. Springer
Supportive Care in Cancer, 27(9), 3563-3572
Supportive Care in Cancer
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b68b1369cff9e7757d7c86e300d49d3
https://research.tilburguniversity.edu/en/publications/c832df0d-a0cc-4cb8-a623-ea6581a27c9b
Tytuł :
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Autorzy :
Robert M. Lorence
P. Carriere
Oliver Gautschi
Wei-Yu Liao
Jin-Yuan Shih
Vito Spataro
Hovav Nechushtan
Alessandra Curioni-Fontecedro
Gee-Chen Chang
James Chih-Hsin Yang
Solange Peters
Agnieszka Cseh
Mojca Unk
Pokaż więcej
Temat :
Adult
Afatinib/therapeutic use
Aged
Aged, 80 and over
Antineoplastic Agents/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/genetics
Carcinoma, Non-Small-Cell Lung/pathology
Female
Follow-Up Studies
Humans
Lung Neoplasms/drug therapy
Lung Neoplasms/genetics
Lung Neoplasms/pathology
Male
Middle Aged
Mutation
Prognosis
Receptor, ErbB-2/genetics
Retrospective Studies
Salvage Therapy
Afatinib
ERBB2 mutation
NSCLC
Clinic for Oncology and Hematology
610 Medicine & health
Pulmonary and Respiratory Medicine
Oncology
medicine.drug
medicine
business.industry
business
Discontinuation
Erlotinib
medicine.medical_specialty
Gefitinib
Exon
Internal medicine
medicine.disease_cause
Receptor tyrosine kinase
biology.protein
biology
Disease control
neoplasms
Źródło :
Journal of thoracic oncology, vol. 13, no. 12, pp. 1897-1905
Peters, Solange; Curioni-Fontecedro, Alessandra; Nechushtan, Hovav; Shih, Jin-Yuan; Liao, Wei-Yu; Gautschi, Oliver; Spataro, Vito; Unk, Mojca; Chih-Hsin Yang, James; Lorence, Robert M; Carrière, Philippe; Cseh, Agnieszka; Chang, Gee-Chen (2018). Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. Journal of Thoracic Oncology, 13(12):1897-1905.
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3a46737805b345849c87401cd2e9620
https://serval.unil.ch/notice/serval:BIB_29FF3A29D783
Tytuł :
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations
Autorzy :
Maria E. Riveiro
Francesco Bertoni
Kay Noel
Ivo Kwee
Eric Raymond
Keyvan Rezai
Elodie Odore
Maurizio D'Incalci
Ramiro Vázquez
Andrea Rinaldi
Esteban Cvitkovic
Roberta Frapolli
Giorgio Inghirami
Lucile Astorgues-Xerri
Mohamed Bekradda
Pokaż więcej
Temat :
Research Paper
OTX015 (MK-8628)
bromodomain
NSCLC
SCLC
KRAS
Acetanilides/pharmacology
Animals
Antineoplastic Agents/pharmacology
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/genetics
Cell Cycle Checkpoints
Cell Line, Tumor
Cell Proliferation
Female
Gene Expression Regulation
Heterocyclic Compounds, 3-Ring/pharmacology
Humans
Lung Neoplasms/drug therapy
Lung Neoplasms/genetics
Mice
Mice, Nude
Mutation/genetics
Protein-Serine-Threonine Kinases/antagonists & inhibitors
Receptor Protein-Tyrosine Kinases/genetics
Small Cell Lung Carcinoma/drug therapy
Small Cell Lung Carcinoma/genetics
Xenograft Model Antitumor Assays
Oncology
Lymphoma
medicine.disease
medicine
Cancer research
BET inhibitor
Cancer
business.industry
business
Stem cell marker
medicine.disease_cause
Cell growth
Immunology
Anaplastic lymphoma kinase
Tumor progression
Źródło :
Oncotarget
Oncotarget, vol. 7, no. 51, pp. 84675-84687
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3baf689a029b4ea760bd7e7c1a28109c
http://europepmc.org/articles/PMC5354535
Tytuł :
Anti-invasive effect of Cyclamen pseudibericum extract on A549 non-small cell lung carcinoma cells via inhibition of ZEB1 mediated by miR-200c
Autorzy :
Karagur, Ege Riza
Ozay, Cennet
Mammadov, Ramazan
Akca, Hakan
Pokaż więcej
Temat :
A549 cells
Cyclamen pseudibericum
EMT
Invasion
Lung cancer
miR-200c
ZEB1
antineoplastic agent
Cyclamen pseudibericum extract
messenger RNA
microRNA 200c
nerve cell adhesion molecule
plant extract
saponin
transcription factor ZEB1
unclassified drug
uvomorulin
vimentin
cadherin
CDH1 protein, human
microRNA
ZEB1 protein, human
A-549 cell line
antineoplastic activity
Article
cancer inhibition
cell invasion
cell invasion assay
cell migration assay
cell proliferation
controlled study
Cyclamen
drug efficacy
drug mechanism
epithelial mesenchymal transition
gene overexpression
gene repression
MIC50
migration inhibition
mRNA expression level
non small cell lung cancer
protein expression
real time polymerase chain reaction
regulator gene
signal transduction
tumor invasion
wound healing assay
ZEB1 gene
antagonists and inhibitors
chemistry
human
lung tumor
metabolism
pathology
tumor cell line
Cadherins
Carcinoma, Non-Small-Cell Lung
Cell Line, Tumor
Humans
Lung Neoplasms
MicroRNAs
Plant Extracts
Zinc Finger E-box-Binding Homeobox 1
A549 Cells
Antigens, CD
Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology
Cyclamen/*chemistry
Lung Neoplasms/*drug therapy/pathology
MicroRNAs/*metabolism
Plant Extracts/*pharmacology
Zinc Finger E-box-Binding Homeobox 1/*antagonists & inhibitors/metabolism
Molecular Medicine
Cancer
medicine.disease
medicine
Cytotoxicity
Cancer cell
Cell growth
Cancer research
Epithelial–mesenchymal transition
Chemistry
Vimentin
biology.protein
biology
A549 cell
Źródło :
Crossref
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f20cde4fab5ec973023491165aaea8d
http://acikerisim.pau.edu.tr:8080/xmlui/handle/11499/10753
Tytuł :
Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer
Autorzy :
Jacobsen, Kirstine
Bertran-Alamillo, Jordi
Molina, Miguel Angel
Teixidó, Cristina
Karachaliou, Niki
Pedersen, Martin Haar
Castellví, Josep
Garzón, Mónica
Codony-Servat, Carles
Codony-Servat, Jordi
Giménez-Capitán, Ana
Drozdowskyj, Ana
Viteri, Santiago
Larsen, Martin R.
Lassen, Ulrik
Felip, Enriqueta
Bivona, Trever G.
Ditzel, Henrik J.
Rosell, Rafael
Pokaż więcej
Temat :
Cell Line
Tumor
Animals
Humans
Mice
SCID
Carcinoma
Non-Small-Cell Lung
Lung Neoplasms
Receptor
Epidermal Growth Factor
DNA Mutational Analysis
Neoplasm Transplantation
Proteomics
Signal Transduction
Apoptosis
Enzyme Activation
Drug Resistance
Neoplasm
Mutation
Female
Proto-Oncogene Proteins c-akt
ErbB Receptors
Article
Journal Article
Science
lcsh:Science
lcsh:Q
Carcinoma, Non-Small-Cell Lung/drug therapy
Cell Line, Tumor
Drug Resistance, Neoplasm
Lung Neoplasms/drug therapy
Mice, SCID
Proto-Oncogene Proteins c-akt/metabolism
Receptor, Epidermal Growth Factor/antagonists & inhibitors
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
General Physics and Astronomy
General Biochemistry, Genetics and Molecular Biology
General Chemistry
Protein kinase B
Growth inhibition
chemistry.chemical_compound
chemistry
Cyclin-dependent kinase 8
EGFR inhibitors
Lung cancer
medicine.disease
medicine
Epidermal growth factor receptor
biology.protein
biology
Signal transduction
Tyrosine-kinase inhibitor
medicine.drug_class
Pharmacology
business.industry
business
Źródło :
Nature communications, vol 8, iss 1
Nature Communications
Jacobsen, K, Bertran-Alamillo, J, Molina, M A, Teixidó, C, Karachaliou, N, Pedersen, M H, Castellví, J, Garzón, M, Codony-Servat, C, Codony-Servat, J, Giménez-Capitán, A, Drozdowskyj, A, Viteri, S, Larsen, M R, Lassen, U, Felip, E, Bivona, T G, Ditzel, H J & Rosell, R 2017, ' Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer ', Nature Communications, vol. 8, 410 . https://doi.org/10.1038/s41467-017-00450-6
Nature Communications, Vol 8, Iss 1, Pp 1-14 (2017)
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3971a73a7b874cb853f9f4c3c3e65794
https://escholarship.org/uc/item/7xc598hg
Tytuł :
The triazole linked galactose substituted dicyano compound can induce autophagy in NSCLC cell lines
Autorzy :
Onur Tokgun
Nilgün Kabay
Hakan Akca
Yasemin Baygu
Yaşar Gök
Ozge Alvur
Pokaż więcej
Temat :
Genetics
General Medicine
Autophagosome
Programmed cell death
Cancer research
Biology
Autophagy
Apoptosis
Cancer cell
TUNEL assay
Cancer
medicine.disease
medicine
Gene expression
Adaptor Proteins, Signal Transducing/metabolism
Antineoplastic Agents
Apoptosis Regulatory Proteins/metabolism
Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism
Cell Line, Tumor
Cell Proliferation/drug effects
Cell Survival/drug effects
Chloroquine/chemistry
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Galactose/*chemistry
Humans
Inhibitory Concentration 50
Lung Neoplasms/drug therapy/*metabolism
Microscopy, Electron, Transmission
Microt
Ambra1
Electron microscopy
LC3B
NSCLC
2,3 bis[1 [2,2,7,7 tetramethyl tetrahydro bis[1,3]dioxolo[4,5 b,4',5' d]pyran 5 methyl] 1h [1,2,3]triazol 4 ylmethylsulfanyl]but 2 enedinitrile
galactose
triazole derivative
unclassified drug
1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one
AMBRA1 protein, human
antineoplastic agent
apoptosis regulatory protein
chloroquine
MAP1LC3B protein, human
microtubule associated protein
naphthyridine derivative
signal transducing adaptor protein
target of rapamycin kinase
antiproliferative activity
Article
autophagosome
carbon nuclear magnetic resonance
controlled study
HCC78 cell line
human
human cell
IC50
immunoblotting
NCI-H1975 cell line
priority journal
protein expression
proton nuclear magnetic resonance
real time polymerase chain reaction
transmission electron microscopy
cell proliferation
cell survival
chemistry
drug effect
drug resistance
drug screening
lung tumor
metabolism
non small cell lung cancer
signal transduction
tumor cell line
Adaptor Proteins, Signal Transducing
Apoptosis Regulatory Proteins
Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Microtubule-Associated Proteins
Naphthyridines
TOR Serine-Threonine Kinases
Triazoles
Źródło :
Crossref
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b49c4e075c2253796d0e5168feb0836
https://api.elsevier.com/content/article/PII:S0378111919305852?httpAccept=text/xml
Tytuł :
Rationale and Study Design of the IRENE-Trial (NVALT-16): A Phase II Trial to Evaluate Iressa Rechallenge in Advanced NSCLC Patients With an Activating EGFR Mutation Who Responded to an EGFR-TKI Used As First-Line or Previous Treatment
Autorzy :
Justine L. Kuiper
Daniëlle A.M. Heideman
Thomas Wurdinger
Katrien Grünberg
Harry J.M. Groen
Egbert F. Smit
Pokaż więcej
Temat :
Cancer Research
Pulmonary and Respiratory Medicine
Oncology
Lung cancer
medicine.disease
medicine
Survival analysis
Response Evaluation Criteria in Solid Tumors
Internal medicine
medicine.medical_specialty
Phases of clinical research
Veristrat
Prospective cohort study
business.industry
business
Gefitinib
medicine.drug
Epidermal growth factor receptor
biology.protein
biology
Immunology
Drug holiday
EGFR
NSCLC
TKI
TKI-resistance
CELL LUNG-CANCER
TYROSINE KINASE INHIBITORS
FACTOR RECEPTOR MUTATIONS
ACQUIRED-RESISTANCE
INITIAL GEFITINIB
OPEN-LABEL
RETROSPECTIVE ANALYSIS
RETREATMENT
CHEMOTHERAPY
ADENOCARCINOMA
Antineoplastic Protocols
Carcinoma, Non-Small-Cell Lung/drug therapy
Clinical Trials as Topic
Drug Resistance, Neoplasm
ErbB Receptors/genetics
Humans
Lung Neoplasms/drug therapy
Mutation/genetics
Prospective Studies
Protein Kinase Inhibitors/administration & dosage
Quinazolines/administration & dosage
Research Design
Survival Analysis
Withholding Treatment
respiratory tract diseases
Źródło :
Crossref
Clinical lung cancer, 16(1), 60-66. CIG MEDIA GROUP, LP
Clinical Lung Cancer, 16(1), 60-66. Elsevier
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3518ca4f76ba2def65ead37923c479ca
https://api.elsevier.com/content/article/PII:S1525730414001508?httpAccept=text/xml
Tytuł :
Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer
Autorzy :
Peters, Solange
Camidge, D. Ross
Shaw, Alice T.
Gadgeel, Shirish
Ahn, Jin S.
Kim, Dong-Wan
Ou, Sai-Hong I.
Pérol, Maurice
Dziadziuszko, Rafal
Rosell, Rafael
Zeaiter, Ali
Mitry, Emmanuel
Golding, Sophie
Balas, Bogdana
Noe, Johannes
Morcos, Peter N.
Mok, Tony
Pokaż więcej
Temat :
Adult
Aged, 80 and over
Animals
Antineoplastic Agents
Carbazoles
Carcinoma, Non-Small-Cell Lung
Central Nervous System Neoplasms
Disease-Free Survival
Female
Follow-Up Studies
Humans
Intention to Treat Analysis
Kaplan-Meier Estimate
Lung Neoplasms
Male
Middle Aged
Piperidines
Protein Kinase Inhibitors
Pyrazoles
Pyridines
Receptor Protein-Tyrosine Kinases
Young Adult
Antineoplastic Agents/adverse effects
Antineoplastic Agents/therapeutic use
Carbazoles/adverse effects
Carbazoles/therapeutic use
Carcinoma, Non-Small-Cell Lung/drug therapy
Carcinoma, Non-Small-Cell Lung/mortality
Central Nervous System Neoplasms/drug therapy
Central Nervous System Neoplasms/secondary
Lung Neoplasms/drug therapy
Lung Neoplasms/mortality
Piperidines/adverse effects
Piperidines/therapeutic use
Protein Kinase Inhibitors/adverse effects
Protein Kinase Inhibitors/therapeutic use
Pyrazoles/adverse effects
Pyrazoles/therapeutic use
Pyridines/adverse effects
Pyridines/therapeutic use
Receptor Protein-Tyrosine Kinases/analysis
Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
General Medicine
Anaplastic lymphoma kinase
Lung cancer
medicine.disease
medicine
Internal medicine
medicine.medical_specialty
Crizotinib
medicine.drug
business.industry
business
Alectinib
Brigatinib
Oncology
Lorlatinib
Ceritinib
ALK inhibitor
medicine.drug_class
Pathology
Źródło :
The New England journal of medicine, vol. 377, no. 9, pp. 829-838
Crossref
Opis pliku :
application/pdf
Dostępność :
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18d35d488c552e94e96cbf18b7922921
http://ddd.uab.cat/record/204741

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies